论文部分内容阅读
Gray实验室最近2-3年才开始做放射防护剂与肿瘤放射治疗关系方面的工作。下面所谈到的我们的工作是今年的新工作,而且是第一次报告这些工作。美国瓦特·瑞医院在这方面做了大量的工作,共实验了大约4400种药物。他们试图找到一些理想的防护剂以便用于核战争中对战士的保护。他们实验的所有化合物内都含有巯基〔(SH)基〕,其中效果最显着的一种是WR-2721。(WR是瓦特·瑞医院的缩写代号2721是指所实验药物的第2721种),其结构式是:NH_2-(CH_2)_3-NH-(CH_2)_2-SH_2-PO_3。名称是S-2(3-aminopropyl-amino)phosphorothioic acid.这个药物的特点是在SH基的后面有一个HPO_3基团,其它的含SH基的化合物由于代谢太快因而对动物的毒性很大,而此化合物必须先脱去“HPCO_3”基团,SH基才能暴露出来起作
Gray Lab began working on the relationship between radioprotectors and radiation therapy for tumors in the last 2-3 years. What we are talking about here is a new job this year and it is the first time that we have reported on these jobs. The U.S. Water Ray Hospital has done a lot of work in this area and has experimented with about 4,400 drugs. They tried to find some ideal protective agents for the protection of soldiers during the nuclear war. All of the compounds they tested contained thiol ((SH)), of which the most significant was WR-2721. (WR is an abbreviation of Wattrui Hospital, code 2721 refers to the 2721st species of the experimental drug) and its structural formula is: NH 2 -(CH 2 )_3-NH-(CH 2 ) 2 -SH_2-PO 3 . The name is S-2(3-aminopropyl-amino)phosphorothioic acid. This drug is characterized by an HPO-3 group behind the SH group. Other SH group-containing compounds are very toxic to animals due to their high metabolism. This compound must first be stripped of the “HPCO_3” group, and the SH group will be exposed